In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
AstraZeneca and Ionis' failed heart disease trial raises questions about the future of RNA drugs
2 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 2 separate news trends connected to Cardio-Ttransform, spanning August 28, 2026 through August 28, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 13 article observations and 11 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
AstraZeneca and Ionis' failed heart disease trial raises questions about the future of RNA drugs
AstraZeneca's failed heart disease drug trial casts doubt on a promising class of treatments